2018-11-06T20:41:14-06:00 2017-12-31 ERNST & YOUNG US LLP TWO NORTH CENTRAL AVENUE STE 2300 PHOENIX AZ 85004 990 2017-01-01 271120123 CREATIVE TESTING SOLUTIONS % TANYA PERRY CREA 6023437016 2424 W Erie Dr TEMPE AZ 852823133 TANYA PERRY CFO 4806755506 2018-10-16 true PATRICK SHIELDS P01508556 6023223000 70.162.72.127 86597020183105000008 2018-11-06 P 006062713DED974B1B9BB64010970EF804E8C5A7 1DEFEEA347AFF02CE3AF0741EDDCF1F60A18EC1E 2017 2018-06-14 16:35:46Z X SALLY CAGLIOTI 2424 W Erie Dr SCOTTSDALE AZ 85257 254728681 false X WWW.MYCTS.ORG X 2009 AZ TO PROVIDE EXCEPTIONAL CUSTOMIZED LABORATORY TESTING SERVICES TO SUPPORT THE HOSPITALS AND OTHER HEALTHCARE ORGANIZATIONS WITH THEIR LIFE SAVING MISSIONS. X 7 6 442 5 108333 746 0 0 239039105 247280016 1153535 1990737 0 0 240192640 249270753 1189390 1310531 0 0 34362664 34640600 0 0 0 186960465 185678395 222512519 221629526 17680121 27641227 119277331 148872194 31236644 148872194 88040687 0 X TO PROVIDE EXCEPTIONAL CUSTOMIZED LABORATORY TESTING SERVICES TO SUPPORT THE HOSPITALS AND OTHER HEALTHCARE ORGANIZATIONS WITH THEIR LIFE SAVING MISSIONS. false false 204927664 1310531 246703366 TESTING OF BLOOD SAMPLES RECEIVED FROM BLOOD DONORS PROVIDED IN CONJUNCTION WITH BLOOD DONATIONS AT NOT-FOR-PROFIT BLOOD CENTERS THROUGHOUT THE COUNTRY AS WELL AS HOSPITALS AND OTHER ORGANIZATIONS, AS REQUIRED BY THE FOOD AND DRUG ADMINISTRATION. SEE SCHEDULE O FOR FURTHER DETAIL. 943467 0 576650 THE CTS RESEARCH PROGRAM IS DEDICATED TO ADVANCING BLOOD SAFETY AND EVIDENCE-BASED TRANSFUSION PRACTICES THROUGH SCIENTIFIC RESEARCH. SEE SCHEDULE O FOR FURTHER DETAIL. 205871131 true false false false false false false false false false true false false false false true true true false false false false false false false false false true false true false false false false false false false false false false false true false true true true false false true 21 0 true 442 true true true false false false false false X 7 6 false false false false true true true true true false false true true true true true true true true false AZ X TANYA PERRY 4806755506 6210 E OAK STREET SCOTTSDALE AZ 85257 JAMES P AUBUCHON MD DIR./SEC./TREAS. (THRU 6/17) 1.0 0.0 X X 0 0 0 SUSAN BARNES DIR.(THRU 2/17)/CFO(THRU 9/17) 14.0 41.0 X X 0 549085 21514 J DANIEL CONNOR DIRECTOR (THRU 5/17) 4.0 51.0 X 0 1268754 36348 JAMES P COVERT DIRECTOR (THRU 2/17) 1.0 0.0 X 0 0 0 DONALD D DODDRIDGE DIRECTOR/CHAIR (THRU 5/17) 2.0 0.0 X X 0 0 0 DAVID GREEN DIRECTOR (STARTED 5/17) 4.0 51.0 X 0 707898 47435 WILLIAM G GREEN DIRECTOR (THRU 4/17) 1.0 2.0 X 0 7000 0 KATHLEEN S PUSHOR DIRECTOR/CHAIR 2.0 3.0 X X 0 31225 0 GEORGE SCHOLL DIRECTOR (STARTED 5/17) 1.0 0.0 X 0 0 0 CHRIS STILES DIRECTOR 1.0 0.0 X 0 0 0 RON WAECKERLIN MD DIRECTOR 1.0 3.0 X 0 47250 0 GARY K WILDE DIRECTOR 1.0 3.0 X 0 31600 0 JOHN WINDHAM DIRECTOR/VICE CHAIR 1.0 0.0 X X 0 0 0 SALLY CAGLIOTI PRESIDENT 55.0 0.0 X 603178 0 36017 TANYA PERRY CFO (STARTED 12/17) 14.0 41.0 X 0 136350 6705 BHAVI SHAH GENERAL COUNSEL/ASST SECRETARY 14.0 41.0 X 0 415746 28665 MARC PEARCE VP, Business Operations 45.0 0.0 X 278751 0 17637 PHILLIP WILLIAMSON PHD VP, Operations 45.0 0.0 X 301484 0 16764 EUGENE ROBERTSON PHD VP, INTEGRATION 40.0 0.0 X 157389 0 3791 JOAN DUNN-WILLIAMS DIRECTOR 45.0 0.0 X 245192 0 17257 RONALD HARDIN SENIOR DIRECTOR 45.0 0.0 X 229435 0 16180 NANCY L HAUBERT DIRECTOR 45.0 0.0 X 219437 0 15598 MICHAEL PHILLIPS DIRECTOR 45.0 0.0 X 210143 0 14971 SHERYL J CYRUS DIRECTOR 45.0 0.0 X 200826 0 18991 2445835 3194908 297873 31 false true false TRICOR AMERICA INC PO BOX 8100 - SFIA SAN FRANCISCO CA 94128 DELIVERY SERVICE 1158589 AEROTEK INC 3689 COLLECTIONS CENTER DR CHICAGO IL 60693 TEMPORARY SERVICES 1055046 MEDIWARE INFORMATION SYSTEMS 11711 W 79TH STREET LENEXA KS 66214 INFO TECH CONSULTANT 1017034 FEDEX PO BOX 7221 PASADENA CA 91109 DELIVERY SERVICE 801437 APEX LIFE SCIENCES 4400 COX ROAD SUITE 200 GLEN ALLEN VA 23060 TEMPORARY SERVICES 567178 15 0 LABORATORY SERVICES 621500 246771683 246771683 RESEARCH & DEVELOPMENT SUPPORT 541700 400000 400000 LABORATORY MANAGEMENT SERVICE FEE 541611 108333 108333 247280016 1142280 1142280 0 0 0 0 0 6306385 5444250 13678 862135 -13678 848457 848457 0 0 0 0 0 0 0 0 0 0 249270753 247171683 108333 1990737 1310531 1310531 0 0 0 1183413 1183413 0 26073200 21987556 4085644 1568469 1411622 156847 3942417 3548175 394242 1873101 1619689 253412 1725155 1725155 245338 245338 39375 39375 0 0 41641 41641 1086629 335323 751306 103229 103229 4078614 3983456 95158 1049169 1038677 10492 0 3670473 3446890 223583 423872 108246 315626 0 0 0 0 2350166 2245452 104714 324618 58953 265665 OPERATING & TESTING SUPPLIES 161627536 161627536 EQUIP LEASES, REPAIRS & MAINT 3180833 3149025 31808 ALL OTHER EXPENSES 5731747 5731747 221629526 205871131 15758395 0 22882786 55838987 0 0 0 0 40495401 30925202 0 0 0 0 0 0 1864149 2579561 558822 1498256 13047940 6410940 7806358 6637000 45569815 51293188 0 0 0 0 0 0 100000 100000 119277331 148872194 31236644 134555638 0 0 0 0 0 0 0 0 0 0 0 14316556 0 0 0 0 31236644 148872194 X 88040687 0 0 0 0 0 88040687 0 119277331 148872194 X 27641227 3718958 -119400872 X false true X true false X 0 2289140 1120194 1168946 0 8685504 4671124 4014380 0 2073296 619622 1453674 6637000 0 0 X 252603389 3718958 3718958 248884431 386322 386322 249270753 221243204 -386322 -386322 221629526 221629526 SCHEDULE D, PART X, LINE 2 AT DECEMBER 31, 2017 AND 2016, THE COMPANY EVALUATED WHETHER IT HAD UNCERTAIN TAX POSITIONS THAT SHOULD BE RECOGNIZED OR DERECOGNIZED BASED ON A 'MORE LIKELY THAN NOT' THRESHOLD FOR TAX POSITIONS TAKEN OR EXPECTED TO BE TAKEN IN A TAX RETURN, INCLUDING THOSE TAX POSITIONS THAT WOULD NOT BE SUSTAINED UPON EXAMINATION IN ACCORDANCE WITH GUIDANCE RELATED TO ACCOUNTING STANDARDS CODIFICATION 740, ACCOUNTING FOR UNCERTAINTY IN INCOME TAXES. THE TAX YEARS FOR THE COMPANY THAT ARE OPEN TO AUDIT BY THE IRS AND STATE DEPARTMENTS OF REVENUE ARE THE TAX YEARS ENDED DECEMBER 31, 2014, THROUGH THE CURRENT TAX YEAR. AS OF DECEMBER 31, 2017 AND 2016, THE COMPANY HAS NOT IDENTIFIED ANY UNCERTAIN TAX POSITIONS THAT WOULD REQUIRE THE RECORDING OF A TAX LIABILITY. THE COMPANY DOES NOT ANTICIPATE A CHANGE IN UNCERTAIN TAX POSITIONS FOR THE 12 MONTHS FOLLOWING THE YEAR ENDED DECEMBER 31, 2017. SCHEDULE D, PART XI, LINE 4B LOSS ON DISPOSAL OF ASSETS - RECLASSED FROM EXPENSES $ (13,678) RESEARCH AND DEVELOPMENT SUPPORT - RECLASSED FROM EXPENSES $ 400,000 --------- TOTAL $ 386,322 SCHEDULE D, PART XII, LINE 2D LOSS ON DISPOSAL OF ASSETS - RECLASSED TO REVENUE $ 13,678 RESEARCH AND DEVELOPMENT SUPPORT - RECLASSED TO REVENUE $(400,000) --------- TOTAL $(386,322) true BLOOD SYSTEMS INC 6210 EAST OAK STREET SCOTTSDALE AZ 85257 860098929 501(C)(3) 1289330 TO BSRI FOR FURTHER RESEARCH SOUTH CENTRAL ASSOCIATION OF BLOOD BANKS 2901 RICHMOND RD LEXINGTON KY 40509 750897961 501(c)(3) 6750 Sponsorship 2 0 SCHEDULE I, PART I, LINE 2 CREATIVE TESTING SOLUTIONS RELIES ON THE RECIPIENT ORGANIZATION'S GOOD GOVERNANCE AND OPERATIONAL PROCEDURES TO SPEND THE MONEY AS INTENDED. X X X true true false false false false false true false SUSAN BARNES DIR.(THRU 2/17)/CFO(THRU 9/17) 0 328685 0 116400 0 104000 0 10800 0 10714 0 570599 0 14205 J DANIEL CONNOR DIRECTOR (THRU 5/17) 0 433237 0 266784 0 568733 0 28800 0 7548 0 1305102 0 159148 DAVID GREEN DIRECTOR (STARTED 5/17) 0 518726 0 177895 0 11277 0 28800 0 18635 0 755333 0 0 SALLY CAGLIOTI PRESIDENT 399291 0 113548 0 90339 0 28800 0 7217 0 639195 0 79639 0 BHAVI SHAH GENERAL COUNSEL/ASST SECRETARY 0 308796 0 96250 0 10700 0 10800 0 17865 0 444411 0 0 MARC PEARCE VP, Business Operations 217252 0 51899 0 9600 0 10800 0 6837 0 296388 0 0 0 PHILLIP WILLIAMSON PHD VP, Operations 235507 0 56377 0 9600 0 10800 0 5964 0 318248 0 0 0 JOAN DUNN-WILLIAMS DIRECTOR 194454 0 43238 0 7500 0 6076 0 11181 0 262449 0 0 0 RONALD HARDIN SENIOR DIRECTOR 185047 0 29773 0 14615 0 7078 0 9102 0 245615 0 0 0 NANCY L HAUBERT DIRECTOR 174246 0 37691 0 7500 0 8755 0 6843 0 235035 0 0 0 MICHAEL PHILLIPS DIRECTOR 164846 0 37797 0 7500 0 8371 0 6600 0 225114 0 0 0 SHERYL J CYRUS DIRECTOR 157370 0 35956 0 7500 0 7992 0 10999 0 219817 0 0 0 EUGENE ROBERTSON PHD VP, INTEGRATION 154066 0 0 0 3323 0 392 0 3399 0 161180 0 0 0 SCHEDULE J, PART I, LINE 4A CERTAIN EMPLOYEES RECEIVED SEVERANCE PAYMENTS DURING 2017 AS FOLLOWS: J. DANIEL CONNOR - $404,635 (PAID BY BSI) SUSAN BARNES - $81,565 (PAID BY BSI) RONALD HARDIN - $14,615 (PAID BY CTS) THESE AMOUNTS ARE TAXABLE AND ARE INCLUDED IN SCHEDULE J, PART II, COLUMN (B)(III). SCHEDULE J, PART I, LINE 4B CERTAIN EMPLOYEES RECEIVED DISTRIBUTIONS FROM THE BSI SUPPLEMENTAL EXECUTIVE RETIREMENT PLAN DURING 2017 AS FOLLOWS: J. DANIEL CONNOR - $159,148 SALLY CAGLIOTI - $79,639 SUSAN BARNES - $14,205 THESE AMOUNTS WERE INCLUDED IN TAXABLE WAGES AND ARE REPORTED IN SCHEDULE J, PART II, COLUMN (B)(III) AND ALSO IN COLUMN (F) SINCE THESE AMOUNTS HAVE PREVIOUSLY BEEN REPORTED AS DEFERRED COMPENSATION ON A PRIOR FORM 990. THIS PLAN WAS FROZEN AS OF DECEMBER 31, 2011. SCHEDULE J, PART I, LINE 7 CREATIVE TESTING SOLUTIONS HAS AN INCENTIVE BONUS PLAN FOR MANAGEMENT AND EXECUTIVES. AWARDS UNDER THE PROGRAM ARE AT THE DISCRETION OF THE BOARD OF TRUSTEES. THE PLAN MEASURES PERFORMANCE AGAINST MULTIPLE METRICS WHICH CARRY VARIOUS WEIGHTINGS, THE MOST HEAVILY WEIGHTED BEING QUALITY, SAFETY AND CUSTOMER SERVICE. TO ASSURE FINANCIAL STABILITY OF THE COMPANY, ONE OF THE METRICS IS ALSO A MEASUREMENT OF NET MARGIN FINANCIAL PERFORMANCE AS A PERCENT OF REVENUES. Transfer of Net Assets 2017-12-31 89550654 Book Value 860098929 BLOOD SYSTEMS INC 6210 E OAK STREET SCOTTSDALE AZ 85257 501(C)(3) Transfer of Net Assets 2017-12-31 29850218 BOOK VALUE 593145469 ONEBLOOD INC 8669 COMMODITY CIRCLE ORLANDO FL 32819 501(C)(3) true true false false SCHEDULE N, PART II ON JANUARY 1, 2017, CREATIVE TESTING SOLUTIONS' ("CTS") MEMBERSHIP INTERESTS WERE BLOOD SYSTEMS, INC. ("BSI") AT 65%, ONEBLOOD, INC. ("ONEBLOOD") AT 25%, THE INSTITUTE FOR TRANSFUSION MEDICINE ("ITXM") AT 5%, AND BLOODWORKS NORTHWEST ("BLOODWORKS") AT 5%. EFFECTIVE MARCH 1, 2017, BSI BECAME THE SOLE MEMBER OF ITXM, AT WHICH TIME ITXM'S MEMBERSHIP INTEREST TRANSFERRED TO BSI AND BSI HELD A 70% MEMBERSHIP INTEREST IN CTS. EFFECTIVE JUNE 16, 2017, BSI ACQUIRED BLOODWORKS MEMBERSHIP INTEREST IN CTS AND BSI HELD A 75% MEMBERSHIP INTEREST IN CTS. ON JULY 25, 2017, CTS, BSI, ONEBLOOD AND THE AMERICAN RED CROSS ("ARC") ENTERED INTO A PLAN OF RECAPITALIZATION AND CONTRIBUTION AGREEMENT WHEREBY CTS WOULD BE RECAPITALIZED ON JANUARY 1, 2018 ("RECAPITALIZATION EFFECTIVE DATE") AND THE TRANSACTION WOULD CLOSE AND DISTRIBUTION WOULD OCCUR ON THE DATE IMMEDIATELY PRECEDING THE RECAPITALIZATION EFFECTIVE DATE. THE RESULTING CTS MEMBERSHIP WOULD BE ARC AT 40%, BSI AT 40%, AND ONEBLOOD AT 20% AS OF THE RECAPITALIZATION EFFECTIVE DATE. SCHEDULE N, PART II, LINES 2A AND 2B CERTAIN OFFICERS AND BOARD MEMBERS OF CTS IN 2017 WERE ALSO OFFICERS AND BOARD MEMBERS OF BSI AND ONEBLOOD, THE TRANSFEREE ORGANIZATIONS, BEFORE THE TRANSFER OF NET ASSETS AND HAVE CONTINUED TO SERVE IN THE SAME ROLES AFTER THE TRANSFER. FORM 990, PART I, LINE 2 AND PART VI, LINE 4 ON JANUARY 1, 2017, CREATIVE TESTING SOLUTIONS' ("CTS") MEMBERSHIP INTERESTS WERE BLOOD SYSTEMS, INC. ("BSI") AT 65%, ONEBLOOD, INC. ("ONEBLOOD") AT 25%, THE INSTITUTE FOR TRANSFUSION MEDICINE ("ITXM") AT 5%, AND BLOODWORKS NORTHWEST ("BLOODWORKS") AT 5%. EFFECTIVE MARCH 1, 2017, BSI BECAME THE SOLE MEMBER OF ITXM, AT WHICH TIME ITXM'S MEMBERSHIP INTEREST TRANSFERRED TO BSI AND BSI HELD A 70% MEMBERSHIP INTEREST IN CTS. EFFECTIVE JUNE 16, 2017, BSI ACQUIRED BLOODWORKS MEMBERSHIP INTEREST IN CTS AND BSI HELD A 75% MEMBERSHIP INTEREST IN CTS. ON JULY 25, 2017, CTS, BSI, ONEBLOOD AND THE AMERICAN RED CROSS ("ARC") ENTERED INTO A PLAN OF RECAPITALIZATION AND CONTRIBUTION AGREEMENT WHEREBY CTS WOULD BE RECAPITALIZED ON JANUARY 1, 2018 ("RECAPITALIZATION EFFECTIVE DATE") AND THE TRANSACTION WOULD CLOSE AND DISTRIBUTION WOULD OCCUR ON THE DATE IMMEDIATELY PRECEDING THE RECAPITALIZATION EFFECTIVE DATE. THE RESULTING CTS MEMBERSHIP WOULD BE ARC AT 40%, BSI AT 40%, AND ONEBLOOD AT 20% AS OF THE RECAPITALIZATION EFFECTIVE DATE. THE BYLAWS OF CTS WERE AMENDED JANUARY 1, 2018 TO REFLECT ALL OF THESE ORGANIZATIONAL CHANGES. FORM 990, PART III, LINES 4A AND 4B 4A) DONOR TESTING BLOOD DONOR TESTING SERVICES PROVIDED BY CREATIVE TESTING SOLUTIONS ("CTS") ARE ESSENTIAL TO ENSURING THE SAFETY OF THE NATION'S BLOOD SUPPLY. THESE TESTING ACTIVITIES ARE ABSOLUTELY NECESSARY AND MANDATED BY THE UNITED STATES FOOD AND DRUG ADMINISTRATION ("FDA") TO PROVIDE A SAFE BLOOD PRODUCT FOR TRANSFUSION TO PATIENTS. DUE TO THE SIGNIFICANT HEALTH RISKS ASSOCIATED WITH THE USE OF HUMAN BLOOD AND BLOOD COMPONENTS, IT IS CRITICAL FOR PUBLIC SAFETY PURPOSES THAT BLOOD BE PROPERLY TESTED BEFORE BEING INTRODUCED INTO THE HEALTHCARE SYSTEM FOR USE BY PATIENTS. A SAFE BLOOD SUPPLY IS CRITICAL TO THE WELL-BEING OF THE NATION'S HEALTHCARE SYSTEM AND ITS PATIENTS. THE SIGNIFICANCE OF THE TESTING OF BLOOD FOR PUBLIC SAFETY IS EVEN MORE PRONOUNCED IN THIS AGE OF THREATS FROM PANDEMICS AND TERRORISM. CREATIVE TESTING SOLUTIONS HAS THREE DONOR TESTING LABORATORIES (DTL). OUR FIRST ESTABLISHED LABORATORY IS IN TEMPE, ARIZONA. THE ADDITIONAL LABORATORIES ARE LOCATED IN BEDFORD, TEXAS AND ST. PETERSBURG, FLORIDA. THESE LOCATIONS ARE STRATEGICALLY POSITIONED NEAR MAJOR AIRPORTS IN PHOENIX, DALLAS AND TAMPA. ALL THREE DTL LABORATORIES ARE FOOD AND DRUG ADMINISTRATION (FDA) REGISTERED FACILITIES AND HOLD CURRENT CERTIFICATIONS FOR THE CLINICAL LABORATORY IMPROVEMENT ACT (CLIA) AS WELL AS ACCREDITATION WITH THE AMERICAN ASSOCIATION OF BLOOD BANKS (AABB), THE NEW YORK STATE DEPARTMENT OF HEALTH, CALIFORNIA DEPARTMENT OF HEALTH SERVICES AND STATE OF FLORIDA AGENCY FOR HEALTH CARE ADMINISTRATION. IN ADDITION TO DONOR SPECIMEN TESTING, THE LABORATORIES PARTICIPATE IN CLINICAL EVALUATION OF REAGENTS, TEST KITS, AND EQUIPMENT. CTS PROVIDES THE HIGHEST QUALITY IN TESTING AND SERVICE. THE LABORATORIES MAINTAIN INTERNAL QUALITY CONTROL PROGRAMS AND PARTICIPATE VOLUNTARILY IN EXTERNAL QUALITY CONTROL PROGRAMS. BLOOD SPECIMENS ARE PROCESSED UTILIZING STATE OF THE ART TECHNOLOGY WITH FDA LICENSED TEST KITS AND REAGENTS. ALL LABORATORIES ARE EQUIPPED WITH MULTIPLE AND REDUNDANT INSTRUMENTS REQUIRED FOR ROUTINE PROCESSING. ADDITIONALLY, EACH FACILITY ACTS AS A BACKUP LABORATORY TO THE OTHER CTS LABS. SPECIAL TESTING OUR SPECIAL TESTING LABORATORIES IN THE PHOENIX AND TAMPA AREAS PERFORM CONFIRMATORY AND SUPPLEMENTAL TESTING OF DONOR SAMPLES AS WELL AS NON-DONATION TESTING SUCH AS DONOR RE-ENTRY, POST EXPOSURE AND DONOR FOLLOW-UP. WE ALSO PROVIDE TESTING FOR EYE BANKS, TISSUE BANKS AND CORD BLOOD CENTERS. THE SPECIAL TESTING LABORATORY ALSO COMPLIES WITH CLIA, FDA, CA, NY, MD, AND FL STATE REGULATIONS. COMPONENT QUALITY CONTROL OUR COMPONENT QUALITY CONTROL LABORATORY IN PHOENIX PROVIDES BLOOD COMPONENT QUALITY CONTROL TESTING. RESIDUAL WHITE BLOOD CELL (RWBC) COUNTS ARE PERFORMED ON LEUKOREDUCED PRODUCTS. FACTOR VIII AND FIBRINOGEN ASSAYS ARE PERFORMED ON CRYOPRECIPITATE AND PLASMA PRODUCTS. BACTERIAL DETECTION IS PERFORMED ON APHERESIS PLATELETS. 4B) RESEARCH AND DEVELOPMENT THE CTS RESEARCH PROGRAM FOCUSES ON THE DEVELOPMENT AND/OR EVALUATION OF NEW BLOOD DONOR SCREENING TECHNOLOGIES WHICH SIGNIFICANTLY IMPROVE AND PROMOTE BLOOD SAFETY IN THE AREAS OF INFECTIOUS DISEASE, IMMUNOLOGY, MOLECULAR DIAGNOSTICS, AND EPIDEMIOLOGY. ADDITIONALLY, THE CTS RESEARCH PROGRAM SERVES AS THE FOCUS FOR A MULTI-INSTITUTIONAL CONSORTIUM WHICH INTEGRATES DATA FROM APPROXIMATELY 35% OF THE US BLOOD SUPPLY FOR THE PURPOSE OF DRIVING THE EVALUATION OF BEST PRACTICES IN TRANSFUSION MEDICINE, THE PROMOTION OF DONOR HEALTH, AND THE IMPROVEMENT OF TRANSFUSION RECIPIENT OUTCOMES. FORM 990, PART VI, LINE 6 CREATIVE TESTING SOLUTIONS HAD TWO NONPROFIT CORPORATE MEMBERS AS OF THE END OF 2017: BLOOD SYSTEMS, INC. ("BSI") AND ONEBLOOD, INC. FORM 990, PART VI, LINE 7A BSI SHALL BE ENTITLED TO DESIGNATE A MAJORITY OF THE NUMBER OF DIRECTORS AT ALL TIMES. FORM 990, PART VI, LINE 7B CERTAIN ACTIONS AND DECISIONS OF THE CORPORATION REQUIRE PRIOR UNANIMOUS APPROVAL FROM CERTAIN MEMBERS PER THE BYLAWS. FORM 990, PART VI, LINE 11B THE FORM 990 IS PREPARED BY AN OUTSIDE ACCOUNTING FIRM BASED ON INFORMATION PROVIDED BY THE CFO AND THE FINANCE TEAM. A COPY OF THE DRAFT FORM 990 AND SCHEDULES IS SUPPLIED TO ALL BOARD MEMBERS PRIOR TO THE MEETING HELD TO ACCEPT THE RETURNS. MEMBERS OF MANAGEMENT REVIEW THE FORM 990 WITH THE BOARD AND ARE AVAILABLE FOR ANSWERING QUESTIONS. ANY COMMENTS FROM THE BOARD ARE CONSIDERED PRIOR TO FILING THE FORM 990 WITH THE IRS. FORM 990, PART VI, LINE 12C EACH YEAR, THE BOARD OF DIRECTORS AND SENIOR MANAGEMENT ARE REQUIRED TO SIGN AND RETURN A CONFLICT OF INTEREST FORM TO COMPANY COUNSEL. ANY CONFLICTS DISCLOSED ARE DISCUSSED WITH THE BOARD AND RESOLVED. IN ADDITION, IN PREPARATION FOR THE FORM 990 FILING, THE DIRECTORS, OFFICERS AND KEY EMPLOYEES IDENTIFIED ARE REQUIRED TO RESPOND TO A COMPREHENSIVE CONFLICT OF INTEREST AND FAMILY RELATIONSHIP QUESTIONNAIRE. ANY CONFLICTS DISCLOSED ARE DISCUSSED WITH THE BOARD AND DISCLOSED APPROPRIATELY ON THE FORM 990. FORM 990, PART VI, LINE 15A AND 15B THE BOARD OF DIRECTORS HIRES AN INDEPENDENT CONSULTING FIRM ONCE EVERY 2-3 YEARS TO PROVIDE DATA ON COMPETITIVENESS OF SALARIES AND BENEFITS FOR CEO AND OTHER OFFICERS OF THE CORPORATION. THE HUMAN RESOURCE DEPARTMENT COLLECTS INFORMATION THROUGH SURVEYS AND OTHER SOURCES IN ADDITION TO THE INDEPENDENT CONSULTING FIRM. NO MEMBERS OF THE BOARD ARE MEMBERS OF MANAGEMENT. COMPENSATION FOR THESE INDIVIDUALS IS SET AND APPROVED BY THE BOARD EACH YEAR. THE RESULTS OF THESE DISCUSSIONS, REVIEWS AND APPROVALS ARE DOCUMENTED IN THE EXECUTIVE SESSION MINUTES OF THE BOARD MEETINGS. THIS PROCESS WAS LAST COMPLETED IN 2017. FORM 990, PART VI, LINE 19 UPON REQUEST, THE FORM 990 CAN BE PRINTED OR VIEWED ON-LINE. UPON WRITTEN REQUEST TO THE CHIEF FINANCIAL OFFICER, A COPY OF THE FORM 990 WILL BE MAILED TO THE REQUESTOR. THE GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY AND FINANCIAL STATEMENTS ARE NOT MADE AVAILABLE TO THE PUBLIC. FORM 990, PART XI, LINE 9 DISTRIBUTION OF EARNINGS - $(119,400,872) BLOOD SYSTEMS INC 6210 E OAK STREET SCOTTSDALE AZ 85257 860098929 BLOOD BANKING AZ 501(C)(3) 10 NA false CANYON STATE INSURANCE COMPANY PO BOX 1085 GRAND CAYMAN CJ KY1-1102 981084327 Captive Ins. CJ NA FOREIGN true BIOCARE INC 6210 E OAK ST SCOTTSDALE AZ 85257 813906720 PHARMA AZ NA C CORP true false true false false false false false false false false true true false false true true false false false BLOOD BANK OF SAN BERNARDINO & RIVERSIDE L 5859112 ACCRUAL LIFESOURCE L 5090345 ACCRUAL CENTRAL BLOOD BANK L 3295036 ACCRUAL VIRGINIA BLOOD SERVICES L 2889707 ACCRUAL BERGEN COMMUNITY REGIONAL BLOOD CENTER INC L 1844796 ACCRUAL Schedule R, Part II THERE ARE VARIOUS RELATED TAX-EXEMPT BLOOD BANKING ORGANIZATIONS THAT ARE INCLUDED IN GROUP EXEMPTIONS, AND THEREFORE, IN ACCORDANCE WITH THE FORM 990 INSTRUCTIONS ARE NOT REPORTED ON SCHEDULE R, PART II.